Skip to main content
Go to homepage

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Treating Younger Patients With T-Cell ALL or Stage II-IV T-Cell Lymphoblastic Lymphoma

Description:

For complete study information, please view the study on clinicaltrials.gov.

Interested in participating?
We are currently recruiting
Full IRB Study Title:
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
IRB Study ID:
986659-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program